SuperworthDBV Technologies EPS DBVT
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.71
- Latest quarter, Q2 FY26
- −$0.12
- Fiscal year 2025
- −$1.05
DBV Technologies' earnings per share was −$0.71 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.12.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.05 | n/a |
| FY2024 | −$6.33 | n/a |
| FY2023 | −$7.70 | n/a |
| FY2022 | −$12.50 | n/a |
| FY2021 | −$17.90 | n/a |
| FY2020 | −$29.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.12 | n/a | −$0.71 | |
| Q1 FY26 | −$0.11 | n/a | −$0.90 | |
| Q4 FY25 | −$0.24 | n/a | −$1.05 | |
| Q3 FY25 | −$0.24 | n/a | −$1.04 | |
| Q2 FY25 | −$0.31 | n/a | −$2.40 | |
| Q1 FY25 | −$0.26 | n/a | −$3.79 | |
| Q4 FY24 | −$0.23 | n/a | −$6.33 | |
| Q3 FY24 | −$1.60 | n/a | −$7.30 | |
| Q2 FY24 | −$1.70 | n/a | −$7.40 | |
| Q1 FY24 | −$2.80 | n/a | −$8.30 | |
| Q4 FY23 | −$1.20 | n/a | −$7.70 | |
| Q3 FY23 | −$1.70 | n/a | −$10.70 |
Against its peers
Companies in Biotechnology nearest DBV Technologies' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| DBVTDBV Technologies | −$0.71 | |
| MGTXMeiraGTx | $0.71 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on DBV Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.